ArticleUrology case reports2024
Primary malignant melanoma of the female urethra A rare histopathology case report.
Article in Urology case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Primary malignant melanoma of the female urethra: A rare case report.Urology case reports · 2025Article
- Ultrasonographic features of female urethral caruncle: a retrospective study of 20 patients.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant melanoma in the urethra is a rare tumor that is difficult to diagnose and treat, leading to a poor prognosis. In this paper, we present the case of a 36-year-old woman with history of invasive rectal adenocarcinoma (PT2N0Mx) who was tumor free for 5 years presented to urology outpatient with history of poor stream, dysuria, and dyspareuria. On examination, there was a huge mass in the meatus of urethra. Urethral malignant melanoma shows a high rate of local recurrence, about 60 % in 1 year. Overall survival in a series of 11 cases at 3 years was 27 %.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.